Simplify Asset Management Inc. Boosts Stock Position in Edwards Lifesciences Corporation $EW

Simplify Asset Management Inc. increased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 92.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,338 shares of the medical research company’s stock after purchasing an additional 9,284 shares during the quarter. Simplify Asset Management Inc.’s holdings in Edwards Lifesciences were worth $1,649,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $266,000. NewEdge Advisors LLC grew its holdings in Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after buying an additional 2,665 shares during the period. Sei Investments Co. grew its holdings in Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after buying an additional 58,988 shares during the period. Squarepoint Ops LLC grew its holdings in Edwards Lifesciences by 277.7% in the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after buying an additional 50,924 shares during the period. Finally, Treasurer of the State of North Carolina grew its holdings in Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after buying an additional 1,065 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,968 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $82.07, for a total value of $818,073.76. Following the sale, the vice president directly owned 22,798 shares of the company’s stock, valued at $1,871,031.86. This trade represents a 30.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Daniel J. Lippis sold 620 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares in the company, valued at $3,278,948.54. This represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 106,684 shares of company stock valued at $8,811,739 over the last three months. Company insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent analyst reports. UBS Group restated a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. BTIG Research lifted their price target on Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a report on Friday, April 24th. Evercore restated an “outperform” rating and issued a $93.00 price target on shares of Edwards Lifesciences in a report on Friday, April 24th. Finally, Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $95.65.

Edwards Lifesciences Stock Performance

Shares of EW opened at $85.93 on Monday. The business’s 50 day moving average is $81.42 and its two-hundred day moving average is $82.89. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $87.89. The firm has a market cap of $49.48 billion, a price-to-earnings ratio of 45.71, a PEG ratio of 2.15 and a beta of 0.87. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business’s revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.